AbbVie adds to the Botox war chest with a 12th FDA approval — but competition is fast approaching
Competition is closing in on AbbVie’s blockbuster Botox franchise — despite the drugmaker’s best efforts to avoid it. In the meantime, the Chicago area drug giant can take some solace in a new indication that will add to the blockbuster drug’s war chest.
The FDA on Wednesday gave Botox the green light to treat detrusor (bladder muscle) overactivity associated with neurological conditions in children 5 and older who were intolerant to or didn’t improve on anticholinergic meds, AbbVie said in a statement. Botox is now the first neurotoxin approved for such use, the drugmaker said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.